Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Insulin Delivery Nov 07 | 2018Insulet Partners with Samsung for Smartphone Pump ControlPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 06 | 2018New Dexcom Approvals; Dexcom and BD Q3 '18 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, SGLT2i Nov 06 | 2018REWIND Safety Issue? Lilly Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA Nov 05 | 2018Positive Trulicity CVOT Creates Many Market ImplicationsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Nov 02 | 2018New Lilly and Novo Trials: Trulicity vs. Ozempic Pens, Fiasp U200, and QW InsulinPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon Nov 02 | 2018Novo Q3 ’18 London Earnings EventPurchase Blast$599
Posted in: Glucose Monitoring Nov 02 | 2018UPDATED: No Approval for Dexcom Verily G1Purchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 01 | 2018Insulet and Tandem Q3 '18 Earnings UpdatesPurchase Blast$599
Posted in: Bolus Insulin, SGLT2i Nov 01 | 2018Lexicon and MannKind Q3 '18 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon Nov 01 | 2018Novo to Pursue High-Dose Ozempic for T2DM; Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: Glucose Monitoring Nov 01 | 2018Dexcom Verily G1 Approved, But Will It Launch?Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal Oct 31 | 2018Sanofi Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: DPP-IVi, SGLT2i Oct 30 | 2018UPDATED: Invokana 3P-MACE Indication ApprovedPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin Oct 26 | 2018Biocon CY Q3 '18 (FY Q2 '19) Earnings UpdatePurchase Blast$599
Posted in: GLP-1RA, GLP-1RA + Basal Oct 26 | 2018Oral Semaglutide + Basal Insulin (PIONEER 8) Positive Topline ResultsPurchase Blast$599
Posted in: Basal Insulin, DPP-IVi, Dual/triple agonist, SGLT2i Oct 25 | 2018Merck Q3 ’18 Earnings Update; No BS-Glargine DiscussionPurchase Blast$599
Posted in: Basal Insulin, GLP-1RA Oct 23 | 2018New Sanofi Efpeglenatide + Glargine Study (AMPLITUDE-L)Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
